Pfizer And GlaxoSmithKline Merger On The Cards

Pfizer and Glaxo merger is said to be the most prominent in the healthcare sector.

Undoubtedly, Pfizer Inc. is the one of the most prominent names out of many pharmaceutical companies in the health care industry. The company’s main objective is to work for a healthier, disease free, and a safe world. It operates its business by producing and selling drugs all across the globe and it has many successful medicines on its portfolio as well.

In previous times, the company tried a lot to acquire AstraZeneca, but failed. However, it managed to sustain and strengthen itself in the market. The latest news suggests that the merger between Pfizer and GlaxoSmithKline is on the cards now.

Rumors started to gather pace regarding Pfizer’s interest to take over its UK-based rival GlaxoSmithKline. This has to be very big news in the health care sector and hence Deutsche Bank’s analyst, Gregg Gilbert, has further ignited fire in these rumors.

Mr. Gilbert has placed a dollar value on this merger deal on Wednesday, which resulted in spreading fire to these speculations. He wrote a note to investors, which was titled ‘Introducing PfizerKline’ and explained that the GlaxoSmithKline buyout or merger would result as ‘materially accretive’ for Pfizer in the coming times. This buyout will further allow the health care giant to ‘unlock access to its balance sheet and improve its tax situation.’

‘Introducing PfizerKline’ stated, “We believe that the company has a sense of urgency to create value by leveraging the power of its balance sheet to do needle-moving deals. Since media reports in the past have pointed to the potential for a Pfizer/GSK combination, we are revisiting that theme.”

Gregg Gilbert further mentioned that this merger would be beneficial for both companies. According to him, the buyout will save the costs of around $3.7 billion or 10% of operating expenses as well. So far, the spokespersons from both parties have declined to comment on the speculations that would result in a massive merger.

The CEO of the company, Ian Read, showed his desire in January of being open for various strategic acquisitions in the future. He stated, “Pfizer is biased toward deals with the potential for creating value in the near term.”

However, many analysts feel that this merger deal might be too hard to chew as well. The company’s failed attempts to acquire AstraZeneca were because of the sheer size. However, GlaxoSmithKline is a much bigger company than AstraZeneca, which has a total workforce of 115,000 throughout the world.

Pfizer Inc. dismissed its partnership with Catalyst Bio caused Targacept to drop by 11%

Pfizer’s decision to dismiss its deal with Catalyst Bio stunned Targacept, who lately entered into a merger contract with Catalyst, betting high on the success of Catalyst-Pfizer partnership.

On Monday, Pfizer Inc. declared that it is planning to dismiss the 2009 agreement between Catalyst Biosciences –a privately held company and Wyeth LLC a fully owned subsidiary of Pfizer Inc. The announcement stuns the Targacept Inc. who lately joined hands with Catalyst in a merger agreement, staking high on the achievement of Pfizer and Catalysts partnership.

The partnership between Catalyst and Wyeth LC was primarily signed in 2009 June, for working along with one another on accelerating the establishment of Catalysts’ foremost Factor Vlla product namely CB813b, to treat hemophilia and patients suffering from surgical bleeding signs. The agreement will expire in June 2015, which will return the research rights and license to Catalyst for its top most candidate product. The pharmaceutical company informed Catalyst to dismiss the license and research contract in an official letter earlier last week.  It has also informed Targacept, on 1^st April, regarding dismissal that will allow them to endure the clinical development of the candidate product by itself.

Targacept at the moment is now evaluating the effect that the company’s extraction from its license contract will have on its most likely merger with the Catalyst. This announcement was made on 5^th March 2015 between the Targacept completely owned affiliate Catalyst and Merger Sub, which will make Catalyst a fully owned affiliate of Targacept. The new joined company will be named as Catalyst Biosciences and will contain a ticker “CBIO”, the coalition will have shareholders of catalyst possessing nearly 65% of ownership in the joined company, while the left 35% of the new company will belongs to Targacept   stockholders, which will also receive in addition to the shares approximately $20 million in cash and around$37 million of dividends through “non-interest-bearing, redeemable, convertible notes.”

Although, the ending decision of the merger agreement is still looking for final consent from the shareholders of the company’s involved and also an approval from the regulatory bodies, the deal is most likely to be close in the 2^nd quarter of the current fiscal year.

On Monday, Targacept Chief Executive Officer, Dr. Stephen Hill while speaking about the outcome if the dismissal of the Pfizer Inc. deal stated that the firm “is currently reviewing the implications of this event on the proposed merger. However, it is too early to know the implications of ending the Pfizer-Catalyst agreement.”

Pfizer stock stood at $34.74 after 0.29% increase on Wednesday market close. The New York City based company had 213.32 billion of market capitalization.